帕博利珠单抗联合乐伐替尼治疗爱泼斯坦-巴尔病毒相关肝内胆管癌取得显著疗效：一例病例报告
Significant response to pembrolizumab plus lenvatinib in Epstein-Barr-virus-associated intrahepatic cholangiocarcinoma: a case report.
作者信息
Li Lisha, Yu Dandan, Yang Jinru, Zhang Fangyuan, Zhang Dejun, Lin Zhenyu, Zhai Menglan, Wang Jing, Zhang Tao, Zhao Lei
机构信息
Cancer Center, Institute of Radiation Oncology, Hubei Key Laboratory of Precision Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
出版信息
Cancer Biol Ther. 2024 Dec 31;25(1):2338644. doi: 10.1080/15384047.2024.2338644. Epub 2024 Apr 22.
BACKGROUND
The prognosis for advanced intrahepatic cholangiocarcinoma (iCCA) is poor, and there remains an urgent need to develop efficient systemic therapy. The efficacy of Pembrolizumab immunotherapy combined with lenvatinibin in iCCA is still unclear. The role of Epstein-Barr-virus (EBV) as a biomarker in iCCA for response to immunotherapy needs further exploration.
CASE PRESENTATION
We report a case of a 60-year-old female with EBV-associated advanced iCCA (EBVaiCCA) who progressed after first-line therapy. She accomplished an available response to the combination therapy of pembrolizumab with lenvatinib, with overall survival of 20 months.
CONCLUSIONS
As far as we know, this is the first case report about the application of Pembrolizumab with lenvatinib for EBVaiCCA patients. This case indicates that the combination of immunotherapy and antiangiogenic therapy provides a glimmer of hope for advanced EBVaiCCA patients.
背景
晚期肝内胆管癌（iCCA）的预后较差，迫切需要开发有效的全身治疗方法。帕博利珠单抗免疫疗法联合乐伐替尼在iCCA中的疗效仍不明确。爱泼斯坦-巴尔病毒（EBV）作为iCCA免疫治疗反应生物标志物的作用有待进一步探索。
病例报告
我们报告一例60岁女性EBV相关晚期iCCA（EBVaiCCA）患者，该患者一线治疗后病情进展。她对帕博利珠单抗联合乐伐替尼的联合治疗取得了有效反应，总生存期为20个月。
结论
据我们所知，这是第一例关于帕博利珠单抗联合乐伐替尼应用于EBVaiCCA患者的病例报告。该病例表明免疫治疗与抗血管生成治疗的联合为晚期EBVaiCCA患者带来了一线希望。
Zotero 插件